Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty

This article was originally published in The Pink Sheet Daily

Executive Summary

Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.

Advertisement

Related Content

Surprise! It’s A Phase III Failure
GSK Likes Its Go-It-Alone Strategy Over A Mega-Merger
Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback
Targeting Inflammation In Atherosclerosis After Darapladib: Does The IL-6 Pathway Hold The Answer?
Is There A Point To Subgroup Analyses Of STABILITY?
Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback
HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
GSK and diaDexus' Rx-Dx Partnership Model

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel